12-17-2010 03:17 AM
'The continued emergence of drug-resistant "superbugs" has created an urgent need for either better antibiotics or an entirely new approach to dealing with infectious diseases. But drug companies hardly seem concerned about investigating any solutions to the problem because they can make more money by devoting their time to creating other, more lucrative drugs, says the head of a prominent medical agency.

Thomas Lonngren, soon-retiring chief of the European Medicines Agency (EMA), recently announced that his organization may need to step up and act as "watchdog" for the pharmaceutical industry to prod it to better meet public health needs. According to Lonngren, there is little incentive for drug companies to work towards creating better antibiotics at this time because the sales of such drugs will only be a fraction of what other potential "blockbuster" drugs will likely be.'

Read more: EU Regulator Slams Drug Companies for Putting Profit Before Public Health